Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts

Core Insights - Royalty Pharma plc (NASDAQ:RPRX) is highlighted as a cheap healthcare stock with strong growth and strategic expansion through acquiring and managing royalties from marketed drugs [1][3] Financial Performance - In Q2 2025, Royalty Pharma reported a 20% increase in Portfolio Receipts to $727 million and an 11% rise in Royalty Receipts to $672 million, driven by royalties from Voranigo, Trelegy, Evrysdi, and Tremfya [2] - The company priced $2 billion in senior unsecured notes in early September 2025 to strengthen liquidity for future royalty acquisitions and investments [5] Strategic Developments - A significant milestone was the acquisition of RP Management, LLC in May 2025, which consolidates intellectual capital and streamlines operations, marking a shift towards a fully integrated public company [3] - Royalty Pharma announced a $2 billion funding arrangement with Revolution Medicines in September, including a synthetic royalty on daraxonrasib, a Phase 3 therapy targeting RAS-addicted cancers [4] Market Engagement - The company released a Deloitte-conducted biopharma royalty market study on September 10, indicating its leadership and active engagement with industry trends that shape its business model and strategy [5]